No Benefit to Postop Heparin Bridging in Patients Who Stop Warfarin for a Procedure No Benefit to Postop Heparin Bridging in Patients Who Stop Warfarin for a Procedure
There does not appear to be a benefit to postoperative heparin bridging in patients with atrial fibrillation or a mechanical heart valve who temporarily stop taking warfarin before a planned procedure, according to results of the PERIOP2 study.Reuters Health Information
CONCLUSIONS: Concomitant left atrial ablation during valve surgery is effective in treating atrial fibrillation. Routine use of anti-arrhythmic medication after surgical ablation is not recommended.PMID:34519328 | DOI:10.5830/CVJA-2021-038
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson &Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) ev...
CONCLUSIONS: Findings suggest that the use DOACs in patients with AF with bioprosthetic valve replacement or repair is comparatively better than vitamin K antagonists in reducing the risk of bleeding and thrombo-embolic events. Future studies with a randomized design and larger sample sizes are needed to further substantiate these findings.PMID:34355372 | DOI:10.26355/eurrev_202108_26457